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Abstract 
Background 
The genetic component of Cannabis Use Disorder (CUD) may overlap with influences acting 
more generally on early stages of cannabis use. This paper aims to determine the extent to 
which genetic influences on the development of cannabis abuse/dependence are correlated 
with those acting on opportunity to use cannabis and frequency of use. 
Methods 
Cross-sectional study of 3303 Australian twins, measuring age of onset of cannabis use 
opportunity, lifetime frequency of cannabis use and lifetime DSM-IV cannabis 
abuse/dependence. A trivariate Cholesky decomposition estimated additive genetic (A), 
shared environment (C) and unique environment (E) contributions to opportunity to use 
cannabis, frequency of cannabis use, cannabis abuse/dependence, and the extent of 
overlap between genetic and environmental factors associated with each phenotype. 
Results 
Variance components estimates were A=0.64 (95% CI 0.58 – 0.70) and E=0.36 (95% CI 
0.29 – 0.42) for age of opportunity to use cannabis, A=0.74 (95% CI 0.66 – 0.80) and 
E=0.26 (95% CI 0.20 – 0.34) for cannabis use frequency, and A=0.78 (95% CI 0.65 – 0.88) 
and E=0.22 (95% CI 0.12 – 0.35) for cannabis abuse/dependence. Opportunity shares 45% 
of genetic influences with frequency of use, and only 17% of additive genetic influences are 
unique to abuse/dependence from those acting on opportunity and frequency. 
Conclusions 
There are significant genetic contributions to lifetime cannabis abuse/dependence, but a 
large proportion of this overlaps with influences acting on opportunity and frequency of use. 
Individuals without drug use opportunity are uninformative, and studies of drug use disorders 
must incorporate individual exposure to accurately identify aetiology. 
Introduction 
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As the legislative landscape regarding cannabis alters, potentially altering patterns of use 
(Hopfer 2014; Hasin et al. 2015; Shi et al. 2015), a greater understanding of environmental 
and genetic influences on progression to harmful or disordered cannabis use is needed. 
Cannabis Use Disorder (CUD) is included in the DSM-5 (American Psychiatric Association & 
DSM-5 Task Force 2013), an amalgamated update of DSM-IV  cannabis abuse and 
cannabis dependence (American Psychiatric Association 2000) characterised by loss of 
control over use, failure to fulfil social roles, recurrent use in hazardous situations, and use 
despite worsening of health problems. An estimated 10% - 16% of individuals who have ever 
used cannabis will develop dependence (Anthony 2006) and globally 13.1 million individuals 
meet criteria for cannabis dependence contributing 10.3% of the illicit drug use global burden 
of disease (Degenhardt et al. 2014).  
Individuals with drug dependence pass through several intermediate stages before 
developing a clinical condition, and many non-clinical individuals will reach earlier stages of 
drug use involvement without progressing to disorder. The earliest stage of involvement is 
having the opportunity to use (regardless of whether the individual uses the drug or not). 
Opportunity is required for use to occur, and forms an individual’s earliest necessary 
condition from which they are at risk of developing dependence (Wagner & Anthony 2002). 
Once initiation of use has occurred, individuals will vary in frequency of cannabis use, with 
increased frequency associated with increased likelihood for the development of cannabis 
dependence (Chen et al. 1997). Considering the sources of variation in progression through 
the stages of cannabis use, and the extent to which influences are consist across different 
stages, can provide insight into the aetiology of CUD (Hines et al. 2015a, 2016).  
Twin modelling has identified a strong genetic contribution to CUD, with a review of 6 
studies in the area concluding heritability estimates range from 45% – 78% (Agrawal & 
Lynskey 2006). Meta-analysis estimated heritability of problematic cannabis use (having one 
or more of the symptoms of cannabis abuse or dependence) at 51.4 (95% CI 37.9–64.9) in 
males and 58.5 (95% CI 44.2–72.9) in females (Verweij et al. 2010). However, the 
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magnitude of these influences may differ across stages of drug use. Early stages may be 
genetically influenced through personality traits such as novelty seeking (Laucht et al. 2007), 
whereas at subsequent stages, such as drug dependence and development of withdrawal, 
genetic influences on drug metabolism, may be more influential (Dick et al. 2014).  
Common genetic influences may act on multiple stages. The majority of research into the 
correlation of influences between initiation of use and disordered use comes from the alcohol 
and tobacco literature, where a genetic correlation (0.15 – 0.88) has been consistently 
demonstrated between the earlier and later stages of drug use (Broms et al. 2006; Pagan et 
al. 2006; Morley et al. 2007). Similarly, studies of alcohol use disorder have identified a 
strong genetic correlation between age of alcohol initiation and alcohol use disorder (Sartor 
et al. 2009; Ystrom et al. 2014). Similar mechanisms may be acting on CUD. Only 34% of 
the variance in cannabis abuse/dependence is unique to this phenotype, with the rest 
shared with genetic influences on initiation (Agrawal et al. 2005), and cannabis availability 
explains almost all the shared environmental risks in cannabis initiation and abuse (Gillespie 
et al. 2009b). 
To date, research has not explored the extent to which genetic influences may correlate 
across more than 2 stages of drug use. Additionally, the heritability of the earliest stage of 
drug use - having opportunity to use a drug (Wagner & Anthony 2002) – has been somewhat 
overlooked. This is despite evidence of the importance of this phenotype for design of 
genetic research (Nelson et al. 2013): individuals who do not have opportunity to use a 
substance are unable to express their genetic vulnerability to later stages, including use and 
use disorders. Not only are such individuals structurally missing in analytic terms, but 
excluding individuals who have no drug use opportunity to use from genetic association 
studies can provide superior control for environmental background and related covariates.  
Opportunity may be regarded as a putative environmental factor, likely subject to broader 
environmental modifications, such as changes in national policy, but also to individual-
specific factors, including peer provision of drugs. Despite these underpinnings, such 
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“environmental” factors have been shown to have heritable variation (Kendler & Baker 2007; 
Gillespie et al. 2009b). Considering this phenotype in the context of later stages of drug 
transitions, such as escalation to frequent use and the development of abuse/dependence 
will provide insight into the pathways to the development of dependence.  
By applying trivariate twin models to the phenotypes age of cannabis opportunity, 
frequency of cannabis use, and abuse/dependence, this paper aims to determine the extent 
to which genetic influences on the development of cannabis abuse/dependence are unique 
to the phenotype, and the extent to which they correlate with influences on opportunity to 
use cannabis and the frequency of cannabis use. 
Methods  
Sample 
The sample was drawn from the Australian Twin Registry. From a pool of pairs born 1972-
1979, 3348 MZ and DZ twins completed the interview component of a study of cannabis and 
other drug misuse. A full description of the study methodology and of the characteristics of 
participants has been published previously (Lynskey et al. 2012). The 3303 twins who 
provided information on whether or not they had ever had the opportunity to use cannabis, 
and who had complete zygosity information, form the analysis sample for this paper. This 
sample consisted of 975 MZ males, 481 DZ males, 734 MZ females, 371 DZ females, and 
742 opposite sex DZ twins. Of these, 808 were singletons. Mean age was 31.8 (range 27 – 
40 years, median 32.0). 
Assessment 
Participants were assessed through computer-assisted telephone interviews which collected 
information on socio-demographics, childhood experiences, drug use and common mental 
health disorders, including cannabis and other drug use disorders, assessed using the Semi-
Structured Assessment for the Genetics of Alcoholism (SSAGA-OZ) interview (Bucholz et al. 
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1994; Heath et al. 1997). The SSAGA-OZ is a validated measure of mental health using 
DSM-IV criteria, and includes assessment of cannabis and other drug abuse and 
dependence. Specific measures used in the current analyses are described below. 
Measures 
Opportunity to use cannabis 
Participants were asked “have you ever been offered, or had the opportunity to use 
cannabis, even if you didn't use it at the time? How old were you the first time?” Of 3348 
twins interviewed, 3325 provided information on whether or not they had ever had the 
opportunity to use cannabis. Of these twins, information on zygosity was missing for 22, 
resulting in an analysis sample of 3303. 
For analysis, participants were categorised as having never had the opportunity to use 
cannabis (N = 356, 10.8%), having had later opportunity to use cannabis (first opportunity 
reported as happening at age 16 and over, N = 2264, 68.5%), or having had early 
opportunity to use cannabis (first opportunity reported as occurring at age 15 or earlier, N = 
670, 20.3%). As there is no precedent in the literature for what age represents an “early” 
opportunity to use cannabis, sensitivity analyses were conducted on the cut-off age. The 
correlations obtained by different cut-off points indicated results were not affected by the 
choice of age 15 as age cut-off for early opportunity (see supplementary material). 
 
Cannabis use frequency 
Participants were asked about lifetime frequency of use through the item “have you used 
marijuana 40 or more times, 21-39 times, 11-20 times, 7-10 times, 1-6 times?”, then 
estimated number of times used. Participants were categorised as having used cannabis 
infrequently, at a level that precluded being asked about cannabis abuse/dependence (0 - 
11 times, N = 1913), moderately (12 – 50 times, N = 476), or high frequency (50+ times, 
N=554).  
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Cannabis abuse/dependence 
Participants were classified as meeting DSM-IV criteria for lifetime cannabis abuse if they 
reported one or more of the following: often using cannabis in a situation where they might 
get hurt; arrested more than twice within a 12 month period as a result of their cannabis use; 
cannabis use having caused difficulty with work, study or household responsibilities; 
cannabis having caused social and interpersonal problems more than 3 times within a 12 
month period.  
Participants were classified as meeting lifetime criteria for DSM-IV cannabis dependence if 
they reported 3 or more of the following symptoms occurring within the same 12 month 
period: using cannabis a greater number of times/greater amount than was intended, 
tolerance, wanting to cut down/stop use, spending so much time obtaining/using/recovering 
from the effects of cannabis the participant had little time for anything else, reducing 
important activities as a result of cannabis use, continuing use despite it worsening 
health/emotional problems. In the sample used in this analysis, 16.4% (N=543) reported 
cannabis abuse and/or dependence. 
Individual characteristics 
Sex 
Sex was determined through self-report (76.9% female, N=2540).   
Zygosity 
Zygosity of twin pairs was measured through standard questions about physical similarity 
and the extent to which twin identity was confused by parents, teachers and strangers; 
methods found to give better than 95% agreement with results of genotyping (Cederlof et al. 
1961; Kasriel & Eaves 1976; Sarna et al. 1978). 
Statistical analyses 
All analyses were conducted using OpenMX v2.5.2 (Boker et al. 2011) for the statistical 
software R v3.1.2 (R Core Team 2013). Analyses used full information maximum-likelihood 
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estimation with raw data, and the optimiser SLSQP was applied to analyses. Analyses were 
adjusted for sex. 
Staged Trivariate Twin Model 
Classical twin modelling estimates the extent to which additive genetic (A), common 
environment (C) and unique environment (E) influence a phenotype (Neale & Cardon 1992). 
Approaches using twins reared together can be used to determine the heritability of, and 
environmental contribution to, a phenotype or trait. Identical – or monozygotic (MZ) – twin 
pairs share 100% of their genetic material. Fraternal – or dizygotic (DZ) – twin pairs share 
only 50%, on average, of the same genetic material. This means they are no more 
genetically alike than full siblings. However, unlike siblings DZ twins will grow up in the same 
environment. Using this knowledge we can calculate the extent to which the variance in a 
phenotype is due to genetic effects, and the extent to which it is due to environmental effects 
(Plomin et al. 2013). If the MZ correlation is twice the DZ correlation then all twin-pair 
similarity can be attributed to A, whereas if the MZ correlation is greater than the DZ 
correlation, but not twice the DZ correlation, there is also evidence of some shared 
environmental influences. The extent to which the MZ twin correlation is less than 1.0 
indicates the magnitude of non-shared environmental influences. Dominant genetic effects 
(D), which are non-additive interaction effects between genes, cannot be assessed 
simultaneously with C (Neale & Cardon 1992). Structural equation modelling of twin data is 
used to obtain precise estimates of A, C and E and allows for the comparison of models and 
generation of confidence intervals around estimates (Neale & Cardon 1992). 
A staged twin model was fitted to assess contributions of A, C, and E to variance in age 
of opportunity to use cannabis, frequency of cannabis use, and lifetime cannabis 
abuse/dependence, and to estimate the extent to which the influences of A, C and E on the 
three phenotypes were correlated (Heath et al. 2002). The staged model is appropriate for 
situations where early-stage phenotypes, such as cannabis use opportunity, are necessary 
for the expression of later behaviours, such as the development of dependence, and is a 
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variation of the classic bivariate model appropriate for analysis of variables with data missing 
at random (data are missing as a result of observations on a previous variable, as opposed 
to data missing completely at random) (Kendler et al. 1999; Heath et al. 2002; Neale et al. 
2006). See Heath et al (2002) for full details. Explicitly modelling such structurally missing 
data also has the advantage of estimating the extent of covariation between these 
contingent stages of use (i.e., opportunity, frequency, abuse/dependence) while not 
excluding those who do not provide information on a prior stage (e.g., opportunity) from 
analyses of later stages (e.g., abuse/dependence). 
A Cholesky decomposition model was used to parse the phenotypic correlations 
between the three stages of cannabis use and misuse into A, C and E sources, including 
those specific to each of the latter stages of frequency and abuse/dependence as well as the 
magnitude of overlapping influences across the 3 stages.  
Assumption testing 
The analysis assumes each threshold-selected trait has an underlying bivariate/multivariate 
normal liability distribution. Exploring this methodological issue falls beyond the scope of this 
paper, but such modelling techniques have been shown to be robust to breaches of this 
assumption (Reinartz et al. 2009). Thresholds represent cut-off points along this unobserved 
continuous distribution of liability. 
In order to test whether thresholds could be equated between MZ and DZ twins, nested 
models were compared against a saturated twin model. Differences in the fit of more 
parsimonious models compared to the saturated or ACE model were assessed via the 
Akaike Information Criterion (AIC) and the change in -2loglikelihood (Δ-2LL), which can be 
approximated by a chi square distribution with degrees of freedom (DF) equal to the 
difference in degrees of freedom of the nested models. Where these measures lead to 
different conclusions on parsimony, the p value has been prioritised. Significance of 
thresholds (and equality between thresholds) was determined by Δ-2LL and change in DF 
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(ΔDF) and associated chi-square distribution. Significance of variance and covariance paths 
was similarly determined through likelihood ratio testing.  
 
Results 
Prevalence of, and Correlations between, Opportunity to use Cannabis, Frequency of 
Cannabis Use and Abuse/dependence 
Of those who reported opportunity to use cannabis by age 15 (N=683), 35.8% (N=244) 
reported high frequency cannabis use (lifetime use 50+ times), compared to 13.7% (N= 310) 
of those who reported cannabis use opportunity at age 16 or older (N=2264). Of those who 
reported high frequency cannabis use (50+ times, N=554), 75.6% (N =418) met criteria for 
lifetime cannabis abuse/dependence compared to 26.3% (N =125) of those who reported 
lower frequency cannabis use (12 – 50 times, N = 476). 
A saturated twin model was used to estimate tetrachoric correlations for the 
categorically-defined traits of age of opportunity, frequency of cannabis use and lifetime 
cannabis abuse/dependence (see Table 1). The relative magnitude of MZ within-trait 
correlations indicate heritable influences on all of these traits. The across twin/across trait 
correlations and confidence intervals indicate genetic factors contribute to all correlations. 
MZ within trait and across trait correlations are not twice the DZ correlations, suggesting 
some influence of C. All correlations are less than 1.0, suggesting moderate to low effects of 
E. 
Assumption Testing 
MZ and DZ thresholds could not be equated (Δ-2LL=15.0, ΔDF=5, P=0.01), and were 
estimated separately in all further models. 
Trivariate Cholesky Model Fitting 
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A saturated model provided fit statistics, estimates for each component of the variance for all 
three phenotypes, and estimates for the covariance between phenotypes. The fit statistics 
for this model were -2LL=11029.68 DF=7249, AIC=--3468.32. 
Nesting Models to Develop Parsimonious Model Fit 
In order to identify the most parsimonious model, nested models constrained individual 
variance and covariance components to zero, when confidence intervals on the estimate 
from the saturated model included 0. It was possible to drop all C parameters (Δ-2LL=6.07, 
ΔDF=6, P value=0.41) without a significant decrement in fit. In addition, there was no 
statistically significant covariance between opportunity and either frequency or 
abuse/dependence attributable to E (Δ-2LL=0.58, ΔDF=2, P value=0.75). 
Final Model 
The final most parsimonious model was an AE model (Δ-2LL=7.22, ΔDF=8, P value=0.51). 
Variance component estimates are presented in Table 2. Approximately 64-78% of the 
variance in each phenotype was due to additive genetic influences, with confidence intervals 
indicating both frequency and abuse/dependence were modestly, but significantly, more 
heritable than opportunity to use. A proportion of these genetic influences were shared 
across the three stages. As shown in Table 2, genetic correlations across stages ranged 
from 0.37 (opportunity and abuse/dependence) to 0.68 (frequency and abuse/dependence). 
For frequency, about 55% of the genetic influences were unique from those acting on 
opportunity, while for cannabis abuse/dependence, 17% of the genetic influences were 
unique from those acting on opportunity and frequency of use. In addition, cannabis 
abuse/dependence shared individual-specific environmental influences with frequency (but 
not opportunity) with 27% specific to this stage. 
Discussion 
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Additive genetic influences determine the majority of variance in age of opportunity to use 
cannabis (0.64, 95% CI 0.58 – 0.70), frequency of cannabis use (0.74, 95% 0.66 – 0.80), 
and cannabis abuse/dependence (0.78, 95% 0.65 – 0.88). Of these influences, 55% of 
additive genetic influences acting on frequency of cannabis use are unique from those acting 
on age of opportunity to use cannabis, and 17% of additive genetic influences acting on 
cannabis abuse/dependence are unique from those acting on opportunity and frequency. No 
significant effect of the shared environment was observed, but there were unique 
environmental influences on all phenotypes. The only correlated unique environmental 
influences were between cannabis use frequency and abuse/dependence. 
 
Previous research has not explored the correlation between influences on cannabis use 
opportunity and cannabis abuse or dependence, although existing studies focusing on 
cannabis initiation observed overlapping liabilities between cannabis initiation and 
progression to heavy use (0.88; 33% due to genetic factors) (Fowler et al. 2007). This is a 
similar genetic contribution to the overlap in liabilities to that presently observed between 
cannabis opportunity and frequency of use. This demonstrates the present findings are in 
line with existing research showing genetic correlation between the early stages of cannabis 
use and later substance use disorders.  
Opportunity to use cannabis is the necessary first step in progression towards 
problematic use, and this phenotype could be expected to be subject only to environmental 
influence. However, 64% of the variance in cannabis age at opportunity was due to genetic 
factors. Although it may be surprising that an apparently environmental phenotype is 
influenced by heritable factors, this result is consistent with previous findings that cannabis 
use availability (Gillespie et al. 2009b) and other putative measures of ‘environment’ 
(Kendler & Baker 2007) are, in fact, influenced by genetic factors. Environmental measures 
can be heritable if there is a bidirectional relationship between an individual’s behaviour and 
their environment, if aspects of behaviour are subject to genetic influences (Kendler & Baker 
2007; Lynskey & Agrawal 2009). A review of this area identified positive and negative life 
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events, divorce and social support all have heritable influences (Kendler & Baker 2007). The 
additive genetic correlation may also indicate evocative or active interactions taking place 
(Plomin et al. 2013), with genes influencing earlier age of cannabis use opportunity 
contributing to individuals selecting into environments and behaviours that facilitate the 
development of cannabis dependence. 
Alternatively, genetic influences associated with other behaviours may be influencing 
progression through the stages of cannabis use. Previous research has identified conduct 
disorder influences transitions to cannabis use opportunity, and from opportunity to 
dependence (Hines et al. 2016). This is in line with existing research demonstrating the 
consistent influence of conduct disorder on drug use (Lynskey et al. 2002; Storr et al. 2011; 
Reboussin et al. 2015), and genes relating to conduct disorder and involvement with deviant 
peers (Gillespie et al. 2009a) are plausible candidates for the shared genetic liability 
between age of opportunity and the development of cannabis abuse/dependence. 
Additionally, personality factors associated with drug use (Malmberg et al. 2010), such as 
sensation seeking, may underlie this shared genetic liability.  
 Cannabis opportunity, frequency of use, and abuse/dependence show a moderate 
effect of the unique environment (0.35, 0.26 and 0.22, respectively), but the correlation 
between unique environmental influences on opportunity and the later stages of drug use 
was non-significant. This may reflect measurement error (Plomin et al. 2013), but is in line 
with existing research demonstrating the pattern of environmental factors associated with 
progression between specific stages of drug use differs between transitions (Sartor et al. 
2007; Belsky DW et al. 2013; Hines et al. 2016). For example, childhood and early 
adolescent factors have been shown to be uniquely associated with cannabis opportunity, 
whereas escalating other drug use factors is uniquely associated with development of 
cannabis dependence (Hines et al. 2016). 
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The present analysis indicated none of the observed variance in opportunity to use 
cannabis, frequency of use or abuse/dependence in males was attributable to the shared 
environment in this sample. The shared environment is usually found to be more important 
at earlier stages than later (Fowler et al. 2007), and these findings contradict findings of a 
high shared environmental  correlation between cannabis availability and cannabis abuse 
(Gillespie et al. 2009b). The samples differ, with the Gillespie et al. findings based on an all-
male population, but these contradictory findings indicate cannabis availability (the perceived 
ease of obtaining cannabis) and opportunity (having been offered cannabis, or being around 
cannabis use) represent different phenotypes.  
Previous research has not tested the extent to which genetic influences on cannabis 
initiation and cannabis abuse overlap, so comparisons cannot be made to the present 
findings for opportunity and abuse/dependence. However, when considered in light of 
findings that variation in progression to subsequent use of cannabis is almost entirely 
attributable to the unique environment (Hines et al. 2015b), a picture is beginning to emerge 
of how different factors influence progression from the very earliest stages of cannabis to the 
development of dependence. 
Implications 
The potential for opportunity to use cannabis to be a marker for intervention has previously 
been discussed (Neumark et al. 2012), and the overlap in genetic influences between age of 
opportunity and both frequency of cannabis use and cannabis abuse/dependence indicates 
there is potential to use this measure to indicate those at greatest risk of developing later 
frequent and/ or problematic use. It has previously been suggested that prevention 
strategies focused on modifying beliefs, norms and behavioural patterns within close social 
networks may be effective at reducing drug use opportunity, and consequently drug use 
(Neumark et al. 2012). The identified moderate influence of unique environmental factors on 
all phenotypes indicates there is scope to determine further influences which may be 
amenable to target within intervention efforts. 
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The findings of this paper have important implications for future studies of gene variants and 
heritability of problematic cannabis use, and in the choice of controls in case-control studies. 
These results indicate only a moderate proportion of genetic influences on cannabis 
abuse/dependence are unique from those acting on age of opportunity to use cannabis. 
These findings reflect previous research demonstrating the importance of considering drug 
use opportunity when looking at the genetics of opiate use (Nelson et al. 2013).  
Comparison of participants in treatment for opiate dependence with nondependent 
neighbourhood controls (high exposure to illicit drugs, either via use or from residing in 
environments with widespread drug availability) identified SNPs in ANKK1 and TTC12 as 
associated with heroin dependence, whereas comparison with controls sourced from the 
ATR (individuals not dependent on alcohol or illicit drugs, with significantly lower illicit drug 
exposure) found no association with these SNPs (Nelson et al. 2013). Until now the 
importance of considering cannabis use opportunity in genetic studies has not been 
explored, although some studies remove those who have not initiated use. Removing those 
who have not initiated cannabis use can reduce sample size and power, and the present 
results indicate excluding those without opportunity may avoid conflating genetic influences 
whilst retaining a greater proportion of a sample. A further advantage of incorporating 
opportunity to use may arise in meta-analyses of genomewide association studies (GWAS) 
of cannabis use and misuse. Marked regional variation in opportunity to use across different 
samples may comprise an international meta-analytic effort. Exclusion of, or accounting for, 
variability in exposure opportunity, even using crude indices of national policy or cannabis-
related law, might reduce heterogeneity in the extent to which genetic vulnerability to later 
stages of cannabis problems have been adequately expressed.  
 Consequently, a key implication of the current findings is the necessity of taking 
into consideration the stage of drug use reached amongst the controls for genomic analyses. 
Existing research has utilised information on the extent of cannabis use in controls (e.g. 
excluding those who had used cannabis fewer than 6 times) (Hartman et al. 2009), but such 
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issues are not always taken into consideration (Benyamina et al. 2009). This may be 
especially important in studies of cannabis; a drug with high prevalence of use, but relatively 
low prevalence of dependence amongst lifetime users. As the legal status of cannabis 
changes (Shi et al. 2015) availability may become to be comparable to that of alcohol, but 
individual opportunity to use may remain variable. Depending on the research question, and 
on the development of research identifying genetic overlap between progression to other 
stages of cannabis use and problematic cannabis use, screening controls not only for 
opportunity or initiation of cannabis use, but also for frequency of use may have utility in 
improving cannabis dependence SNP identification in the future.  
 These findings have further implications for the overlap of genetic influences 
across drug classes. Existing research has suggested a proportion of the genetic factors 
underlying SUDs are not specific to individual drugs, and environmental influences 
determine the drug of misuse (Kendler et al. 2003) However, previous research in this area 
has not incorporated consideration of the stage sequential nature of drug dependence into 
their analyses. Much of the non-specificity of genetic influences on SUDs likely results from 
shared influences on the earlier stages of drug use, with more specific influences (such as 
those related to drug metabolism, for example) associated with later stages of use. 
 
Limitations 
Certain limitations must be taken into account when interpreting these results. The data are 
based on retrospective self-report. Retrospective recall of age onset of drug use behaviours 
has been shown to be reliable (Shillington et al. 1995; Johnson & Mott 2001; Parra et al. 
2003; Ensminger et al. 2007), but the analyses would benefit from replication in prospective 
longitudinal cohorts. Self-report has been shown to be a valid measure of data collection 
relating to drug use (Darke 1998), and has been described as the gold standard for 
collecting data on phenotypes such as initiation and opportunity (Wagner & Anthony 2002). 
Given use of cannabis was illegal at time of data collection, some participants in this study 
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may have misreported their drug use. However, the high prevalence of self-reported lifetime 
cannabis use (68.5%) suggest it’s unlikely this was an issue. 
The results are based on a twin population. Research has demonstrated twin and non-
twin populations do not differ in incidence of psychiatric illness (Kendler et al. 1996), and no 
association has been found between twin environmental similarity and mental health 
outcomes (Kendler et al. 1993).  
Conclusions 
There are significant genetic contributions to lifetime cannabis abuse/dependence, but a 
proportion of this overlaps with genetic influences acting on the opportunity to use cannabis 
and the frequency of cannabis use. Individuals without drug use opportunity are 
uninformative, and studies of drug use disorder and frequency of use, whether focused on 
identifying gene variants or environmental factors, must incorporate consideration of drug 
use exposure use amongst controls in order to accurately identify aetiological factors.  
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Table 1: Tetrachoric correlations (95% confidence intervals) between age of opportunity to 
use cannabis and cannabis abuse/dependence in MZ and DZ twin pairs 
 
 Within trait, across twin correlation Across trait, across twin correlation 
Age of 
Opportunity  
twin 1/twin 2 
Frequency 
cannabis use 
twin 1/twin 2 
Abuse/ 
Dependence 
Twin 1/twin 2 
Age of 
Opportunity / 
Frequency 
cannabis use 
Age of 
Opportunity / 
Abuse/ 
Dependence 
Frequency 
cannabis use/ 
Abuse/ 
Dependence 
MZ 
N = 1709 
0.65 
(0.57 – 0.71) 
0.72 
(0.63 – 0.75) 
0.79 
(0.66 – 0.82) 
0.48 
(0.40 – 0.55) 
0.37 
(0.26 – 0.48) 
0.67 
(0.65 - 0.75) 
DZ 
N = 1594 
0.36 
(0.26 – 0.45) 
0.48 
(0.38 – 0.58) 
0.37 
(0.26 – 0.48) 
0.31 
(0.22 – 0.38) 
0.22 
(0.12 – 0.33) 
0.41 
(0.29 – 0.52) 
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Table 2: Proportion of variance (95% CI) attributable to additive genetic (A), shared 
environment (C) and unique environment (E) factors in the fully estimated and in the most 
parsimonious model 
  Opportunity Frequency Dependence Correlation 
Opportunity 
– Frequency 
Correlation 
Opportunity 
–
Dependence 
Correlation 
Frequency – 
Dependence 
Fully 
estimated 
ACE model 
A 0.57 
(0.34 – 0.69) 
0.46 
(0.22 – 0.70) 
0.64 
(0.33 – 0.84) 
0.35 
(0.18 – 0.54) 
0.27 
(0.08 – 0.46) 
0.49 
(0.24 – 0.70) 
C 0.07 
(0.00 – 0.27) 
 
0.25 
(0.04 – 0.45) 
0.13 
(0.00 – 0.38) 
0.13 
(-0.03 – 027) 
0.09 
(-0.05 – 
0.23) 
0.18 
(0.02 – 0.38) 
E 0.35 
(0.28 – 0.43) 
 
0.28 
(0.23 – 0.36) 
0.23 
(0.13 – 0.36) 
 
-0.02 
(-0.08 – 
0.05) 
 
0.01 
(-0.08 - 0.10) 
0.22 
(0.14 – 0.31) 
 
Parsimonious 
AE model 
A 0.65 
(0.58 – 0.72) 
0.74 
(0.66 – 0.80) 
 
0.78 
(0.65 – 0.88) 
0.47 
(0.41 – 0.52) 
0.37 
(0.30 – 0.44) 
 
0.68 
(0.59 – 0.75) 
E 0.35 
(0.29 – 0.42) 
0.26 
(0.20 – 0.34) 
0.22 
(0.12 – 0.35) 
- - 0.21 
(0.14 – 0.29) 
 
 
